This is a StreetInsider.com Premium Only Page

(PRTG) – StreetInsider.com Reports

Apr 17, 2024 04:06 PM Biohaven Pharma (BHVN) Announces Proposed Public Offering of Common Shares

Apr 12, 2024 08:01 AM Portage Biotech (PRTG) to Expand Evaluation of Strategic Alternatives

Feb 28, 2024 05:16 PM Portage Biotech Inc. (PRTG) Misses Q4 EPS by 161c

Jan 8, 2024 12:46 PM H.C. Wainwright Downgrades Portage Biotech inc. (PRTG) to Neutral

Jan 4, 2024 08:01 AM Portage Biotech (PRTG) to pause further drug development in the PORT-2 iNKT program

Nov 30, 2023 06:34 AM Portage Biotech inc. (PRTG) PT Lowered to $6 at H.C. Wainwright

Oct 31, 2023 04:09 PM Portage Biotech (PRTG) Announces 9.63M Share Offering by Selling Stockholders

Oct 16, 2023 07:12 AM Biohaven Pharma (BHVN) Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass

Oct 2, 2023 04:37 PM Biohaven Pharma (BHVN) Announces $200M Proposed Public Offering Of Common Shares

Sep 29, 2023 08:01 AM Portage Biotech (PRTG) Announces $6 Million Registered Direct Offering of Common Stock, Warrants

Aug 2, 2023 08:11 AM Portage Biotech inc. (PRTG) PT Lowered to $9 at H.C. Wainwright

Jul 31, 2023 05:20 PM Portage Biotech Inc. (PRTG) Misses Q2 EPS by 98c

Jul 31, 2023 09:32 AM Biohaven Pharma's (BHVN) Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy

Jul 31, 2023 07:00 AM Biohaven Pharma (BHVN) Reports Q2, Provides Update on Recent Business Developments

Jul 27, 2023 07:02 AM Biohaven Pharma (BHVN) Provides Preliminary EEG Data Update for Kv7 Platform

May 31, 2023 07:04 AM Biohaven Pharma (BHVN) Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day

Feb 21, 2023 07:30 AM Biohaven Pharma (BHVN) Announces Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy

Dec 1, 2022 06:29 AM Portage Biotech inc. (PRTG) PT Lowered to $21 at H.C. Wainwright

Nov 30, 2022 04:43 AM Portage Biotech inc. (PRTG) PT Lowered to $18 at Oppenheimer

Nov 8, 2022 08:02 AM Portage Biotech (PRTG) Announces Clinical Trial Collaboration Agreement with Merck (MRK)

Oct 18, 2022 04:13 PM Biohaven Pharma (BHVN) Announces Launch of 20M Share Public Offering of Common Shares

Oct 4, 2022 07:35 AM Biohaven Pharma (BHVN) launches today as a new publicly traded company

Sep 29, 2022 08:27 AM Biohaven Pharma (BHVN) says Verdiperstat did not statistically differentiate from placebo in Pivotal Phase 2/3 Trial

Sep 20, 2022 07:00 AM Portage Biotech inc. (PRTG) PT Lowered to $22 at H.C. Wainwright

Sep 14, 2022 08:40 AM Portage Biotech (PRTG) Issues Research and Development Update

Aug 18, 2022 08:05 AM Portage Biotech (PRTG) announces Dr. Ian Walters, CEO, will be appointed Chairman

Jul 20, 2022 09:03 AM Portage Biotech (PRTG) Acquires Remaining 22% Stake in Invariant Natural Killer T cell (iNKT) Agonist Platform

Jul 18, 2022 09:17 AM Oppenheimer Assumes Portage Biotech inc. (PRTG) at Outperform

May 23, 2022 07:16 AM Biohaven Pharma (BHVN) Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia Did Not Reach Statistical Significance

Apr 27, 2022 06:45 AM Pfizer (PFE) and Biohaven’s (BHVN) VYDURA Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine

Apr 25, 2022 08:05 AM Portage Biotech (PRTG) Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity

Apr 1, 2022 07:32 AM Biohaven Pharma (BHVN) Announces Nurtec Lactation Clinical Study Published in Breastfeeding Medicine Journal

Mar 7, 2022 06:28 AM UPDATE: H.C. Wainwright Starts Portage Biotech inc. (PRTG) at Buy

Feb 25, 2022 07:00 AM Biohaven Pharma (BHVN) Pfizer (PFE) Receive Positive CHMP Opinion for Migraine Treatment

Feb 25, 2022 06:53 AM Biohaven Pharma (BHVN) Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb (BMY)

Feb 14, 2022 07:01 AM Biohaven Pharma (BHVN), Pfizer (PFE) Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea

Jan 5, 2022 07:04 AM Biohaven Pharma (BHVN), Pfizer (PFE) Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States

Dec 6, 2021 07:32 AM Biohaven Pharma (BHVN) Announces Positive Topline Results from Pivotal Migraine Trial of Intranasal Zavegepant

Dec 6, 2021 07:30 AM Biohaven Pharma (BHVN) Names CEO Vlad Coric, MD, Chairman Of The Board Of Directors And Matthew Buten, Chief Financial Officer

Nov 9, 2021 07:47 AM Biohaven Pharma (BHVN) and Pfizer (PFE) announce strategic collaboration for the global commercialization of NURTEC ODT outside the United States

Oct 5, 2021 07:33 AM Biohaven Pharma (BHVN) Announces Preliminary 3Q Net Product Revenue For NURTEC ODT

Sep 27, 2021 07:01 AM Biohaven Pharma (BHVN) Phase 3 Trial of verdiperstat in multiple system atrophy (MSA) Did Not Statistically Differentiate from Placebo

Sep 21, 2021 05:44 AM UPDATE: Oppenheimer Starts Portage Biotech inc. (PRTG) at Outperform

Sep 2, 2021 06:02 AM B.Riley Starts Portage Biotech inc. (PRTG) at Buy

Jun 24, 2021 09:26 AM Pre-Open Stock Movers 06/24: (MRIN) (RCUS) (LLY) Higher; (PRTG) (RAD) (BIIB) Lower (more...)

Jun 24, 2021 09:04 AM Portage Biotech (PRTG) Prices 1M Share Offering at $23/each

Jun 23, 2021 06:06 PM After-Hours Stock Movers 06/23: (DHX) (RCUS) (CXM) Higher; (PRTG) (TALO) (KBH) Lower (more...)

Jun 23, 2021 04:14 PM Portage Biotech (PRTG) Announces Proposed Share Offering, Size not Disclosed

Jun 17, 2021 04:01 PM Biohaven Pharma (BHVN) Appoints Kishen Mehta to its Board

May 27, 2021 05:13 PM Biohaven Pharma (BHVN) Announces FDA Approves its NURTEC ODT Migraine Medication for Acute and Preventive Treatment